Academic Journal
Anticancer drug-induced interstitial lung disease: a critical appraisal of clinical practice guidelines and consensus statements.
| Τίτλος: | Anticancer drug-induced interstitial lung disease: a critical appraisal of clinical practice guidelines and consensus statements. |
|---|---|
| Συγγραφείς: | Zhang Y; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.; Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China., Ma Z; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Sun X; Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, China., Zhang Y; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Zhu M; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Zhang S; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Feng X; Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China., An Z; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. |
| Πηγή: | Expert opinion on drug safety [Expert Opin Drug Saf] 2026 Jun; Vol. 25 (6), pp. 1093-1101. Date of Electronic Publication: 2024 Feb 20. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Ashley Publications, c2002- |
| Ιατρικοί όροι (MeSH): | Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/administration & dosage , Lung Diseases, Interstitial*/chemically induced , Practice Guidelines as Topic*/standards , Consensus Statements as Topic*, Biomarkers/metabolism ; Steroids/administration & dosage ; Humans |
| Περίληψη: | Anticancer drug-induced interstitial lung disease (DIILD) has received increasing clinical attention, and the quality of relevant guidance documents has become critical. Our purpose was to assess the quality of documents for anticancer DIILD and summarize the recommendations. Clinical practice guidelines (CPGs) and consensus statements with recommendations were searched in electronic databases, websites of guideline organizations, and professional societies. The quality of documents was assessed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) methodology, and the specific recommendations were aggregated and compared. A total of 11 documents were eligible, including 6 CPGs and 5 consensus statements, and the quality of AGREE II assessments differed greatly. The domains of scope and purpose and clarity of presentation received the highest median scores, while the stakeholder involvement domain received the lowest score. Recommendations were inconsistent between documents, particularly regarding the selection of steroid regimens. The methodological quality of the guidance documents needs to be enhanced, especially in the domain of stakeholder involvement. Inconsistencies exist in documents, and further discussions among multidisciplinary experts are needed. Particularly, differences in steroid regimens require attentions, and researches on the risks of adverse events and discovery of precise biomarkers are necessary. |
| Contributed Indexing: | Keywords: AGREE II; Anticancer drug; clinical practice guideline; consensus statement; interstitial lung disease; pneumonitis |
| Substance Nomenclature: | 0 (Antineoplastic Agents) 0 (Biomarkers) 0 (Steroids) |
| Entry Date(s): | Date Created: 20240207 Date Completed: 20260601 Latest Revision: 20260602 |
| Update Code: | 20260602 |
| DOI: | 10.1080/14740338.2024.2315113 |
| PMID: | 38323333 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!